Showing 7191-7200 of 7665 results for "".
- Revance Therapeutics Added to Russell 2000(R) and 3000(R) Indexeshttps://practicaldermatology.com/news/20140401-revance_therapeutics_added_to_russell_2000r_and_3000r_indexes/2459286/Revance Therapeutics, Inc. (Nasdaq:RVNC), today announced the company was added to the Russell 2000® and Russell 3000® Indexes following the reconstitution of Russell Investment Group's family of U.S. indexes after market close on March 31, 2014.
- Image Skincare Releases Vectorize Technology™https://practicaldermatology.com/news/20140401-image_skincare_releases_vectorize_technology/2459287/Vectorize Technology has revolutionized ingredient delivery by enabling up to 100 treatments in a single application. Marc Ronert, M.D., Ph.D., President and Medical Director of Image Skincare said, "Vectorize Technology™ is a game-changer. It will revolutionize the way the world thinks a
- ZO Medical Products Launches in the Middle Easthttps://practicaldermatology.com/news/20140331-zo_medical_products_launches_in_the_middle_east/2459288/ZO Skin Health and Cellogique launched ZO products at the Dubai World Dermatology & Laser Conference Exhibition. Dr. Zein Obagi, board certified dermatologist, developed this product with hopes of representing his skin health principles. “These products empowe
- Merz North American Provides Educational Grant to Support Dermatology Board Review Systemhttps://practicaldermatology.com/news/20140327-merz_north_american_provides_education_grant_to_support_dermatology_board_review_system/2459291/Merz North America recently provided an educational grant to fund the Derm In-Review system that helps residents prepare for their Board certifying exams free of charge. The system, which has helped prepare more
- Merz Aesthetics To Launch New Physician Loyalty Programhttps://practicaldermatology.com/news/20140326-merz_aesthetics_to_launch_new_physician_loyalty_program_my_merz_select/2459293/Merz Aesthetics, a division of Merz North America, announced the upcoming launch of its completely new physician loyalty program, My Merz Select, which will go live on April 1, 2014. My Merz Select is a simple, transparent pro
- Provectus Biopharmaceuticals Inc. Submits Application to FDA to Receive Breakthrough Therapy Designation for PV-10 for Treatment of Melanomahttps://practicaldermatology.com/news/20140325-provectus_biopharmaceuticals_inc_submits_application_to_fda_to_receive_breakthrough_therapy_designation_for_pv-10_for_treatment_of_melanoma/2459296/Provectus Biopharmaceuticals, Inc. (OTCQB:PVCT) (http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, announced today that it has applied to the FDA for Breakthrough Therapy Designation (BTD) for PV-10 for the treatment of melanoma. FDA guidelines state that
- Anti-Interleukin-23 Monoclonal Antibody Guselkumab: Significant Efficacy In Moderate To Severe Plaque Psoriasishttps://practicaldermatology.com/news/20140324-anti-interleukin-23_monoclonal_antibody_guselkumab_significant_efficacy_in_moderate_to_severe_plaque_psoriasis/2459298/New findings presented for the first time at the 2014 Annual Meeting of the American Academy of Dermatology (AAD) showed up to 86 percent of patients with moderate to severe plaque psoriasis receiving guselkumab (CNTO 1959) achieved a Physician's Global Assessment (PGA) score of cleared or minimal a
- ADAM Names June McKernan “Practice Manager Of The Year”https://practicaldermatology.com/news/20140323-adam_names_june_mckernan_practice_manager_of_the_year/2459299/The Association of Dermatology Administrators and Managers (ADAM) named June McKernan, Administrator, of Patient Preferred Dermatology of Los Alamitos, CA, the recipient of the organization's inaugural Practice Manager of the Year award. She w
- Phase 3 Results for Novartis' Secukinumab Reportedhttps://practicaldermatology.com/news/20140322-phase_3_results_for_novartis_secukinumab_reported/2459300/Results from the Phase III FEATURE and JUNCTURE studies show Novartis' secukinumab (AIN457), a selective interleukin-17A (IL-17A) inhibitor, met both co-primary endpoints at Week 12 based on Psoriasis Area and Severity Index (PASI) 75 and Investigator's Global Assessment modified 2011 (IGA mod 2011)
- Novan Announces Positive Phase 2 Results for Novel Acne Treatmenthttps://practicaldermatology.com/news/20140321-novan_announces_positive_phase_2_results_for_novel_acne_treatment/2459303/Novan Therapeutics announced today positive Phase 2 study results of its topical SB204 drug candidate for the treatment of acne vulgaris. Acne is a skin disease that affects more than fifty million people in the United States. The Phas